N Engl J Med 355 (26): 2733-43, 2006.[PUBMED Abstract] Andr√© F, O'Regan R, Ozguroglu M, et al.: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol 15 (6): 580-91, 2014.[PUBMED Abstract] Robson M, Im SA, Senkus E, et al.: Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
N Engl J Med 377 (6): 523-533, 2017.[PUBMED Abstract] Litton JK, Rugo HS, Ettl J, et al.: Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med 379 (8): 753-763, 2018.[PUBMED Abstract] Ettl J, Quek RGW, Lee KH, et al.: Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.